ClinicalTrials.gg
CompletedNCT03747575Updated May 6, 2023Results posted

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of MSTT1041A and Placebo in Atopic Dermatitis, sponsored by Genentech, Inc.. Completed at 21 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
311th of 544
65 · median 96
Started
2019
with 57 others
Phase 2
202 of 639
18 open now
Registered
299th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 311th largest by enrollment of the 544 interventional ones that give a count, is one of 58 that started in 2019, is one of 202 in phase 2, and was the 299th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comply with the study protocol
  • Chronic AD that has been present for at least 3 years before the screening visit
  • Documented recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications (medications or treatments applied directly to part of the body) or for whom topical treatments are otherwise medically inadvisable

Exclusion criteria

Exclusion criteria

  • Prior treatment with MSTT1041A
  • Treatment with any therapy (with the exception of biologics) within 8 weeks or within 5 half-lives whichever is longer, before screening
  • Treatment with any cell-depleting agents within 6 months before screening, or until lymphocyte count returns to normal, whichever is longer
  • Treatment with other biologics within 3 months or 5 half-lives before screening, whichever is longer
  • Comorbid conditions that may interfere with evaluation of investigational medicinal product
  • History or evidence of substance abuse that would pose a risk to participant safety, interfere with the conduct of the study, have an impact on the study results, or affect the participant's ability to participate in the study
  • History of anaphylaxis, to a biologic agent, or known hypersensitivity to any component of the MSTT1041A or placebo injection
  • Planned surgical intervention during the course of the study
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Participant who is a member of the investigational team or his/her immediate family
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Treatment

    Participants will receive MSTT1041A

    Drug: MSTT1041A

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to MSTT1041A

    Drug: Placebo

Interventions

  • Participants will receive subcutaneous (SC) MSTT1041A

    Also known as: astegolimab

  • DrugPlacebo

    Participants will receive SC placebo

06

What researchers measure

Primary outcomes

  1. Percent Change of Total Eczema Area and Severity Index (EASI) Score

    The Eczema Area and Severity Index (EASI) is a standardized instrument to evaluate the extent and severity of atopic dermatitis. An area score comprised of the percentage of skin affected by eczema for each of 4 body regions (head/neck, trunk, upper extremities, and lower extremities) is calculated with 0 = none, 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, and 6 = 90-100%. Severity is scored for each of the 4 body regions by the summation of the intensity scores for 4 signs (redness, thickness, scratching, and lichenification), with 0 = none/absent, 1 = mild, 2 = moderate, and 3 = severe. The minimum final EASI score is 0 and the maximum score is 72.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1

    Time frame: Baseline, Week 16

  2. Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score

    Time frame: Baseline, Week 16

  3. Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS)

    The Peak Pruritis Numerical Rating Scale (NRS) is a single-item patient-reported outcome (PRO) of itch severity rated on a scale of 0-10, with 0 = no itch and 10 = worst itch imaginable for the prior 24-hour period.

    Time frame: Baseline, Week 16

  4. Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement

    Time frame: Baseline, Week 16

  5. Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)

    SCORAD is a tool used to assess the extent and severity of eczema based on three aspects of disease severity: extent, intensity, and a subjective (PRO) symptoms. A total score (0-103) is calculated, with higher scores indicating a higher extent and severity of symptoms.

    Time frame: Baseline, Week 16

  6. Percentage of Participants With Adverse Events (AE)

    Time frame: Up to Week 24

  7. Serum Concentrations of MSTT1041A

    Time frame: At pre-defined intervals from baseline up to Week 24

  8. Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)

    Time frame: Up to Week 24

07

Results

Posted May 6, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboTreatment
Started3233
Completed2326
Not completed97
Withdrew: Withdrawal by subject63
Withdrew: Lost to follow-up33
Withdrew: Adverse event01

Outcome measures

PrimaryPercent Change of Total Eczema Area and Severity Index (EASI) Score

The Eczema Area and Severity Index (EASI) is a standardized instrument to evaluate the extent and severity of atopic dermatitis. An area score comprised of the percentage of skin affected by eczema for each of 4 body regions (head/neck, trunk, upper extremities, and lower extremities) is calculated with 0 = none, 1 = 1-9%, 2 = 10-29%, 3 = 30-49%, 4 = 50-69%, 5 = 70-89%, and 6 = 90-100%. Severity is scored for each of the 4 body regions by the summation of the intensity scores for 4 signs (redness, thickness, scratching, and lichenification), with 0 = none/absent, 1 = mild, 2 = moderate, and 3 = severe. The minimum final EASI score is 0 and the maximum score is 72.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percentage
Percent Change of Total Eczema Area and Severity Index (EASI) Score
PercentageTreatmentPlacebo
Percent Change of Total Eczema Area and Severity Index (EASI) Score-51.47 ± 8.639-58.24 ± 9.092
SecondaryProportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1
Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 1
PercentageTreatmentPlacebo
Proportion of Participants Who Achieve Investigator's Global Assessment (IGA) Response of 0 or 115.26.3
SecondaryProportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score
Time frame:
Baseline, Week 16
Reported as:
Number · Percentage
Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score
PercentageTreatmentPlacebo
Proportion of Participants Who Achieve >/=75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) Score27.318.8
SecondaryPercent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS)

The Peak Pruritis Numerical Rating Scale (NRS) is a single-item patient-reported outcome (PRO) of itch severity rated on a scale of 0-10, with 0 = no itch and 10 = worst itch imaginable for the prior 24-hour period.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percentage
Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS)
PercentageTreatmentPlacebo
Percent Change in Pruritus as Assessed by a Numeric Rating Scale (NRS)-31.22 ± 7.376-39.43 ± 7.839
SecondaryPercent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement
Time frame:
Baseline, Week 16
Reported as:
Mean · Percentage
Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement
PercentageTreatmentPlacebo
Percent Change in Body Surface Area (BSA) With Atopic Dermatitis (AD) Involvement-42.23 ± 8.637-38.87 ± 9.134
SecondaryPercent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)

SCORAD is a tool used to assess the extent and severity of eczema based on three aspects of disease severity: extent, intensity, and a subjective (PRO) symptoms. A total score (0-103) is calculated, with higher scores indicating a higher extent and severity of symptoms.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percentage
Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)
PercentageTreatmentPlacebo
Percent Change in Disease Severity as Assessed by SCORing Atopic Dermatitis (SCORAD)-35.45 ± 6.837-39.50 ± 7.202
SecondaryPercentage of Participants With Adverse Events (AE)
Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Percentage of Participants With Adverse Events (AE)
ParticipantsTreatmentPlacebo
Percentage of Participants With Adverse Events (AE)1418
SecondarySerum Concentrations of MSTT1041A
Time frame:
At pre-defined intervals from baseline up to Week 24
Reported as:
Geometric mean · ug/mL
Serum Concentrations of MSTT1041A
ug/mLTreatment
Day 1 Visit 2/prior to infusionNA ± NA
Week 1 Visit 3/prior to infusion42.6 ± 34.4
Week 4 Visit 5/prior to infusion37.6 ± 52.5
Week 8 Visit 7/prior to infusion36.6 ± 54.5
Week 12 Visit 9/prior to infusion40.1 ± 60.5
Week 16 Visit 1138.2 ± 76.0
Subject disposition - period completion/early discontinuation7.83 ± 151.2
SecondaryIncidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)
Time frame:
Up to Week 24
Reported as:
Number · Participants
Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)
ParticipantsTreatmentPlacebo
Incidence of Treatment-Emergent Anti-Drug Antibodies (ADAs)10

Adverse events

Collected over Up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/31 (0%)0/31 (0%)8/31 (25.8%)
Treatment0/34 (0%)1/34 (2.9%)3/34 (8.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboTreatment
Aortic aneurysmVascular disorders0/311/34
Most frequent other events
Most frequent other events
EventPlaceboTreatment
Dermatitis atopicSkin and subcutaneous tissue disorders5/313/34
NasopharyngitisInfections and infestations3/310/34
Abdominal painGastrointestinal disorders2/310/34

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboTreatmentTotal
<=18 years000
Between 18 and 65 years303161
>=65 years224
Age, Continuous
Age, Continuous(Years)PlaceboTreatmentTotal
Mean39.3 ± 14.439.7 ± 15.239.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTreatmentTotal
Female202040
Male121325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTreatmentTotal
Hispanic or Latino224
Not Hispanic or Latino303060
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTreatmentTotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American8816
White202545
More than one race000
Unknown or Not Reported000
08

Study locations

21 sites
  • Alabama Allergy & Asthma
    Birmingham, Alabama 35209, United States
  • California Allergy and Asthma Medical Group - CRN
    Los Angeles, California 90025, United States
  • Jonathan Corren MD, Inc.
    Los Angeles, California 90025, United States
  • Asthma & Allergy; Associates, P.C.
    Colorado Springs, Colorado 80907, United States
  • South Coast Research Center, Inc.
    Miami, Florida 33136, United States
  • Harmony Clinical Research, Inc
    North Miami Beach, Florida 33162, United States
  • GCP Global Clinical Professionals
    Saint Petersburg, Florida 33702, United States
  • Forward Clinical Trials
    Tampa, Florida 33624, United States
  • Florida Pulmonary Research Institute, LLC
    Winter Park, Florida 32789, United States
  • Midwest Sinus Allergy and Asthma - CRN
    Normal, Illinois 61761, United States
  • Dermatology Specialists Research, LLC
    Louisville, Kentucky 40241, United States
  • Clinical Research Consortium Nevada
    Las Vegas, Nevada 89119, United States
  • Skin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS
    Hackensack, New Jersey 07601, United States
  • Vital Prospects Clinical Research Institute PC - CRN
    Tulsa, Oklahoma 74136, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Centrum Medyczne ALL-MED
    Krakow, 30-033, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
  • Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina; Klinika Dermatologii
    Rzeszow, 35-055, Poland
  • Laser Clinic
    Szczecin, 70-322, Poland
  • Wro Medica
    Wroc?aw, 51-685, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2020, 13 months.

Results were first posted in May 2023, 3 years 1 month after primary completion. A results delay was requested in Mar 2021.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2018
First posted
Nov 20, 2018
StartActual
Feb 6, 2019
Primary completionActual
Mar 11, 2020
CompletionActual
May 5, 2020
Results delay requested
Mar 8, 2021
Results first posted
May 6, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03747575
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Feb 6, 2019
Primary completion
Mar 11, 2020
Completion
May 5, 2020
Results posted
May 6, 2023
Last update
May 6, 2023

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion